New triple therapy aims to tame tough diabetes
NCT ID NCT07244003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three diabetes drugs (metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist) versus other oral medications in adults with type 2 diabetes who have poor blood sugar control. The goal is to see which combo works better at lowering blood sugar, blood pressure, and cholesterol. About 430 participants aged 18-75 will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Inflammatory diet tame type 2 diabetes?
- New diabetes combo pill aims to beat single drugs in major trial
- New combo therapy aims to improve diabetes management
- New triple therapy aims to protect kidneys in diabetes patients
- New combo diabetes pill tested in healthy volunteers
- New diabetes pill put to the test: does food change how it works?